New drugs; palifermin
Cohen, A.F.; Dubois, E.A.; van Bronswijk, H.
Nederlands Tijdschrift Voor Geneeskunde 150(50): 2753-2754
2006
ISSN/ISBN: 0028-2162 PMID: 17225787 Document Number: 602177
Palifermin is a human keratinocyte growth factor that is produced in Escherichia coli by recombinant-DNA-technology. This substance protects against oral mucositis in adults undergoing myeloablative therapy. The safety of this product--being a growth factor --in the long term has not yet been shown. Adverse effects may occur in the skin and mucous membranes.
Document emailed within 1 workday
Related Documents
Lee, M.; Grassi, M. 2010: Acanthosis nigricans in a patient treated with palifermin Cutis 86(3): 136-137Rzepecki, P.; Sarosiek, T.; Barzal, J.; Oborska, S.; Nurzynski, P.; Wasko, A.; Szczylik, C. 2007: Palifermin for prevention of oral mucositis after haematopoietic stem cell transplantation- single centre experience Journal of BUON: Official Journal of the Balkan Union of Oncology 12(4): 477-482
Lucchese, A.; Matarese, G.; Manuelli, M.; Ciuffreda, C.; Bassani, L.; Isola, G.; Cordasco, G.; Gherlone, E. 2016: Reliability and efficacy of palifermin in prevention and management of oral mucositis in patients with acute lymphoblastic leukemia: a randomized, double-blind controlled clinical trial Minerva Stomatologica 65(1): 43-50
Wrześniok, D.; Buszman, E.; Matusiński, B. 2003: Drugs ototoxicity. Part II. Loop diuretics, nonsteroidal anti-inflammatory drugs, antineoplastic and antimalarial drugs Wiadomosci Lekarskie 56(7-8): 369-374
McGettigan, P.; Roderick, P.; Mahajan, R.; Kadam, A.; Pollock, A.M. 2015: Use of Fixed Dose Combination (FDC) Drugs in India: Central Regulatory Approval and Sales of FDCs Containing Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Metformin, or Psychotropic Drugs PLOS Medicine 12(5): E1001826; Discussion E1001826
Marek, J. 1985: On the non-specific antiinflammatory effects of other-than-antirheumatic drugs. Psychotropic drugs, inflammation and antiinflammatory drugs International Journal of Tissue Reactions 7(6): 475-504
Yanaginuma, T. 1984: Clinical pharmacology for midwives. 3. Pregnancy and drugs. 3. Drugs with their risk superseding the benefits Josanpu Zasshi 38(6): 526-530
Wong, I.C. 1997: New antiepileptic drugs. Study suggests that under a quarter of patients will still be taking the new drugs after six years Bmj 314(7080): 603-604
Degkwitz, R. 1980: Psychotropic drugs. Sense and nonsense in the prescription of sedating, psycholeptic and hypnotic drugs Zfa. Zeitschrift für Allgemeinmedizin 56(2): 77-83
Nargeolet, H. 1972: Misuse of drugs and excess of self-administered drugs. Administrative and legislative problems Therapie 27(2): 289-295
Villette, B.; Rybojad, M.; Puissant, A. 1989: Dermatologic manifestation of undesirable effects of drugs (excluding cytostatic drugs) Annales de Medecine Interne 140(7): 609-613
Allen, L.V. 1995: Drugs, devices and delivery considerations in parenteral pharmaceutical care, or, what are they doing with our drugs? PDA Journal of Pharmaceutical Science and Technology 49(6): 306-308
Jacob, J.; Barthelemy, C. 1972: Misuse of drugs and excess of self-administered drugs. Problems posed for the pharmacologist Therapie 27(2): 189-217
Beresewicz, M.; Bidzińska, E.; Koszewska, I.; Puzyński, S. 1991: Results of using tricyclic antidepressive drugs in the treatment of endogenous depression (comparative analysis of 7 drugs) Psychiatria Polska 25(3-4): 13-18
Imai, S. 1975: Action mechanism of anti-hypertensive drugs, with special reference to beta blocking drugs Nihon Jinzo Gakkai Shi 17(7): 674-677
2015: New drugs and indications in 2014. Some advances this year, but many drugs are poorly evaluated, too expensive, or more dangerous than useful Prescrire International 24(159): 107-110
Biour, M.; Poupon, R.; Grange, J.D.; Chazouillères, O.; Lévy, V.G.; Jaillon, P. 1997: Hepatotoxicity of drugs. 10th update of the bibliographic database of hepatic involvements and responsible drugs Gastroenterologie Clinique et Biologique 21(10): 660-696
Holland, M.G. 1974: Autonomic drugs in ophthalmology: some problems and promises. I. Directly and indirectly acting parasympathomimetic drugs Annals of Ophthalmology 6(5): 447-450 Passim
Fernández de Córdova-Rodríguez1, L.R.é; Guzmán-Guillén, K.A.; Fernández de Córdova-Aguirre, J.C. 2015: DRESS syndrome or reaction to drugs with eosinophilia and systemic symptoms associated to anti-tuberculosis drugs Revista Alergia Mexico 62(2): 149-156
Panicker, G.K.; Karnad, D.R.; Salvi, V.; Kothari, S. 2012: Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs Journal of the Association of Physicians of India 60: 56-61